
Late-Breaking Research – Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023
SUZHOU, China, April 17, 2023 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023). The AACR Annual Meeting is the largest cancer meeting in the world, gathering high-quality oncology […]...

